Molecular Medicine
Tri-Conference Plenary Session

The Molecular Medicine Tri-Conference celebrates its 25th anniversary in February 2018. Tri-Con originally started in the mid-1990s as three separate, back-to back conferences during the Human Genome Project, and stretched over 7 days: The Human Genome Project: Commercial Implications meeting, The Genetic Screening and Diagnosis of Human Diseases meeting, and The Genomic Partnering Forum. These meetings merged and over the years, other programs were added - but the term 'Tri-Con' has stuck.

Tri-Con has been and will continue to be a platform in recognizing the potential for new technologies and research in molecular medicine, diagnostics, drug discovery, and drug development that have a pivotal role in mitigating disease, improving access to healthcare, and identifying transformative treatments.

In honor of Tri-Con's 25th anniversary, we assembled key individuals like Leroy Hood and David Haussler who have had a seminal role in the HGP, to provide unique perspectives of genomic medicine over the years and visions for the future. Their presentations and others in the plenary keynote program will inspire you to continue efforts in developing novel medicines, diagnostics, therapeutics, and approaches to gain a greater understanding of the underpinnings of cancer and advance personalized medicine. We plan for Tri-Con to celebrate its 50th anniversary in 2043, and perhaps you'll be a featured speaker?

Join approximately 1,000 of your colleagues in each of these plenary keynote presentations. These are the only times each day that bring all attendees from the 16 conference programs together in one room.


MONDAY, FEBRUARY 12

5:00 - 6:00 pm

5:00 Welcome Remarks

Scientist.com_landscape 5:05 Plenary Keynote Introduction

Daniel Kagan, PhD, COO, Scientist

5:15 Plenary Keynote Presentation: Systems (P4) Medicine, Big Data and Scientific Wellness Are Transforming Healthcare

Leroy HoodLeroy Hood, MD, PhD, President and Co-founder, Institute for Systems Biology; Senior Vice President & Chief Science Officer, Providence St. Joseph Health

Systems medicine, the application of systems approaches to disease, places medicine at a fascinating tipping point-promising a revolution in the practice of healthcare. I will discuss how systems biology approaches have framed systems medicine and I will discuss some of the new systems-driven technologies and strategies that have catalyzed this tipping point. Moreover, four converging thrusts-systems medicine, big data (and its analytics), the digitalization of personal measurements and patient-activated social networks-are leading to a proactive healthcare that is predictive, personalized, preventive and participatory (P4). I will contrast P4 healthcare, embodying 21st Century Medicine, with contemporary medicine and discuss its societal implications for healthcare. P4 healthcare has two central thrusts-wellness and disease. I will discuss our successful effort to introduce P4 healthcare into the current healthcare system with a P4 pilot program on scientific wellness-a longitudinal, high-dimensional data cloud study on each of 108 well patients over 2014. The preliminary results both with regard to data analyses and patient responses from these studies are striking. They point to the emerging discipline of scientific wellness-and the fact that it will catalyze several new thrusts in healthcare: 1) optimizing wellness, 2) identifying the earliest disease transitions for all common diseases and learning how to reverse them and 3) employing the dense, dynamic, personal data cloud approach to study diseases (e.g. cancer, Alzheimer's, diabetes) and their responses to therapy. Scientific wellness will also pioneer N=1 experiments to de-convolute the staggering complexity of human biology and disease. We started Arivale, a company focused on scientific wellness for the consumer, in 2015 and already have about 3500 individuals enrolled. I will also discuss some preliminary results from the Arivale studies.

My institute, the Institute for Systems Biology (ISB), in 2016 affiliated with Providenc St. Joseph Health to become its research arm and I became its Chief Science Officer. Providence is one of the largest non-profit healthcare systems in the US-and ISB/Providence will be initiating a series of "translational pillars" moving applications of systems (P4) medicine from the bench to the bedside. These clinical trial pillars include scientific wellness, bringing scientific wellness to cancer survivors, making early Alzheimer's a reversible and preventive disease, rather than a relentlessly progressive disease, taking a systems approach to type 2 diabetes and exploring how the deep, dynamic, personal data clouds can be used to gain a deep understanding of glioblastoma and provide new diagnostic and therapeutic approaches to this inevitably fatal tumor. It is fair to say that dense, dynamic, personal data clouds followed longitudinally on hundreds of thousands of patients/consumers will allow us to see the earliest wellness to disease transitions for all of the common cancers-and generate biomarkers for early detection and identify the drug targets or strategies (e.g., immunotherapy) that will allow us to reverse the disease before it ever manifests itself as a disease phenotype-this will be the preventive medicine of the 21st century. Systems medicine, P4 healthcare and scientific wellness are the central pillars of 21st Century Medicine and will open up powerful new approaches to dealing with diseases of the skin-including psoriasis.

Thus, scientific wellness will catalyze a transformation in contemporary healthcare and it will provide eventually millions of dense, dynamic, personal data clouds that will present striking new opportunities for pharma, biotech, nutrition and diagnostic companies to identify biomarkers and drug target candidates. As the cost of the assays for the dense, dynamic, personal data clouds decline dramatically; scientific wellness can eventually be brought to the developing world leading to a democratization of healthcare unimaginable even a few years ago. 

Biographical profile: Dr. Hood's outstanding contributions have had a resounding effect on the advancement of science since the 1960s. Throughout his career, he has adhered to the advice of his mentor, Dr. William J. Dreyer: "If you want to practice biology, do it on the leading edge, and if you want to be on the leading edge, invent new tools for deciphering biological information." Hood was involved in the development of six instruments critical for contemporary biology-namely, automated DNA sequencers, DNA synthesizers, protein sequencers, peptide synthesizers, the ink jet printer for constructing DNA arrays and large scale synthesis of DNA and the nanostring instrument for the single molecule analysis of RNA (and later DNA). These instruments opened the door to high-throughput biological data and the era of big data in biology and medicine. He helped pioneer the human genome program-making it possible with the automated DNA sequencer. Under Hood's direction, the Human Genome Center sequenced portions of human chromosomes 14 and 15. In 1992, Hood created the first cross-disciplinary biology department, Molecular Biotechnology, at the University of Washington. In 2000, he left the UW to co-found Institute for Systems Biology (ISB), the first committed to systems approach to biology and disease. He has pioneered systems medicine in the years since ISB's founding and has argued for a healthcare that is predictive, preventive, personalized and participatory (P4). Hood has made many seminal discoveries in the fields of immunology, neurobiology, cancer biology and biotechnology and, most recently, has been a leader in the development of systems biology and its applications to cancer and neurodegenerative diseases, as well as pioneering technologies and strategies that bring systems biology to personalized medicine. Hood is now pioneering new approaches to P4 medicine and most recently, has embarked on creating a P4 pilot project on 108 well individuals, that is transforming healthcare and leading to a new healthcare discipline termed scientific wellness. In addition to his ground-breaking research, Hood has published 750 papers, received 36 patents, 17 honorary degrees and more than 100 awards and honors. He is one of only 15 individuals elected to all three National Academies-the National Academy of Science, the National Academy of Engineering, and the Institute of Medicine. Hood has founded or co-founded 15 different biotechnology companies including Amgen, Applied Biosystems, Rosetta, Darwin, Integrated Diagnostics, Indi Molecular and Arivale. Dr. Hood has also had a life-long interest in K-12 science education and ISB has been a leader in this area.

6:00 Grand Opening Reception in the Exhibit Hall with Poster Viewing


TUESDAY, FEBRUARY 13

8:00 - 9:00 am

8:00 am Welcome Remarks

Flagship Bioscience8:05 Plenary Keynote Introduction

Joseph Krueger, PhD, CSO, Flagship Biosciences

8:15 State of the Industry Report: Cancer Research

Sara_RedcliffeSara Radcliffe, President & CEO, California Life Sciences Association

Biographical profile: Sara Radcliffe was appointed the president and CEO of the California Life Sciences Association (CLSA) in December 2014. She formerly served as the Executive Vice President for Health at the Biotechnology Industry Organization (BIO). Previously, Sara served as Senior Director, Biologics & Biotechnology at the Pharmaceutical Research and Manufacturers of America (PhRMA). She also served in the Alliance and Technology Group at SmithKline Beecham Pharmaceuticals as a Research and Development Policy Analyst, working on evaluation and communication of the promise, ethics, and impact of rapidly-developing technologies in DNA research. In addition, she worked for the Core Services Committee of the New Zealand Ministry of Health. Sara holds a Master of Public Health and a Master of Arts in Philosophy from the Johns Hopkins University, and a Bachelor of Arts from Wellesley College.

8:30 Plenary Keynote Presentation

Walking on the Moon: Reflections on the Work of the Cancer Moonshot and the Future of the Biden Cancer InitiativeGregory Simon

Gregory C. Simon, JD, President, Biden Cancer Initiative
Nixon's War on Cancer faced an outlook for success as bleak as the Moon's surface with no understanding of the genetic complexity of cancer, no therapeutic weapons, and no grand strategy. The Cancer Moonshot provided the leadership to harness the millions of scientists and patients, powerful new therapies, and cultural changes needed to double our rate of progress against cancer. The Biden Cancer Initiative is now continuing the movement to double our rate of progress in preventing, detecting, diagnosing and treating cancer.
Biographical profile: Greg Simon served as the Executive Director of the White House Cancer Moonshot Task Force, a position created by President Barack Obama and for which he was chosen by Vice President Joe Biden in March 2016. Over nine months, Greg and his team helped launch over seventy innovative collaborations. Greg returned to the White House after serving as Vice President Al Gore's Chief Domestic Policy Advisor between 1993 and 1997. Greg was the CEO of Poliwogg, a financial services company creating unique capital market opportunities in healthcare and life sciences. Previously, he was Senior Vice President for Worldwide Policy and Patient Engagement at Pfizer, co-founded with Michael Milken, FasterCures/ The Center for Accelerating Medical solutions, and with Leon and Debra Black co-founded the Melanoma Research Alliance. Greg is a cancer survivor, having been recently successfully treated for chronic lymphocytic leukemia.

9:00 Refreshment Break in the Exhibit Hall with Poster Viewing


WEDNESDAY, FEBRUARY 14

8:00 - 10:00 am

8:00 Welcome Remarks

Diagnostics World Early Innovator Award logo8:05 Diagnostics World Early Innovator Award Program


8:15 Plenary Keynote Presentation

David_HausslerDavid Haussler, PhD, Distinguished Professor and Scientific Director, UC Santa Cruz Genomics Institute, University of California, Santa Cruz

Biographical profile: David Haussler develops new statistical and algorithmic methods to explore the molecular function, evolution, and disease process in the human genome, integrating comparative and high-throughput genomics data to study gene structure, function, and regulation. He is credited with pioneering the use in genomics of hidden Markov models (HMMs), stochastic context-free grammars, and discriminative kernel methods. As a collaborator on the international Human Genome Project, his team posted the first publicly available computational assembly of the human genome sequence on the Internet on July 7, 2000. His team subsequently developed the UCSC Genome Browser, a web-based tool that is used extensively in biomedical research and serves, along with the Ensembl platform, virtually all large-scale vertebrate genomics projects, including NHGRI's ENCODE project, the 1000 Genomes Project, and NCI's TCGA. He built the CGHub database to hold NCI's cancer genome data and is a co-founder and organizing member of the Global Alliance for Genomics and Health (GA4GH), a coalition of the top research, health care, and disease advocacy organizations that have taken the first steps to standardize and enable secure sharing of genomic and clinical data. Haussler received his Ph.D. in Computer Science from the University of Colorado, Boulder. He is a member of the National Academy of Sciences and the American Academy of Arts and Sciences and a fellow of AAAS and AAAI. He has won a number of awards, including the 2014 Dan David Prize, in the Future category, 2011 Weldon Memorial prize for application of mathematics and statistics to biology, 2009 ASHG Curt Stern Award in Human Genetics, the 2008 Senior Scientist Accomplishment Award from the International Society for Computational Biology, the 2006 Dickson Prize for Science from Carnegie Mellon University, and the 2003 ACM/ AAAI Allen Newell Award in Artificial Intelligence.

8:45 Plenary Session Panel: Emerging Technologies and Industry Perspectives

This panel session will feature a series of presentations on emerging and hot technologies in molecular medicine. Each speaker will have 7 minutes at the podium. After all speakers have presented, there will be a moderated Q&A with attendees. The presentations are not meant to be a corporate or specific product pitch. Each speaker will focus on a technology and solution framed around a motivational clinical problem and how their particular company/organization is solving it.

Moderators/Chairpersons:

Kristin Ciriello Pothier, Global Head of Life Sciences, Parthenon-EY

Scott Palmer, Senior Vice President and Head of Precision Medicine, Parthenon-EY

Panelists:

Martha Najib, Director, Business Development, Ximedica
Christopher Mueller, PhD, President & CTO, Lab7 Systems
Florian Bell, Senior Member, Technical Staff, Sensor System Integration, Qorvo
Tim Wesselman, CEO, OnRamp Bioinformatics Inc
Erik Vossenaar, PhD,Vice President, Business Development, Biocartis
Siamak Baharloo, PhD, Labviva 
Christopher Ianelli, MD, Ph.D., CEO, iSpecimen 
Speaker to be Announced, NanoString

 

 

10:00 Refreshment Break and Poster Competition Winner Announced in the Exhibit Hall

* 活動內容有可能不事先告知作更動及調整。


Choose your language
Chinese
Japanese
Korean
English



目錄下載
Catalog


免費電子郵件通知服務